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Purpose: The impact of family history on the diagnosis of the prostate cancer among Asian population remains controversial. We 
evaluated whether a positive family history of the prostate cancer in Korean men is associated with the diagnosis and aggressive-
ness of the prostate cancer.
Materials and Methods: Patients who underwent a transrectal ultrasound-guided prostate biopsy from March 2015 to September 
2017 were evaluated. Information on family history was obtained via a self-administered questionnaire. The presence of prostate 
cancer and clinically significant prostate cancer (Gleason score ≥7) was evaluated according to the presence of a family history.
Results: Of 602 patients (median age, 68.3 years; median prostate-specific antigen level, 6.28 ng/mL), 41 (6.8%) patients had a 
family history of prostate cancer. Family history was a significant factor for detecting prostate cancer (odds ratio [OR], 2.99; 95% 
confidence interval [CI], 1.330–6.704; p=0.008). In multivariate analysis for predicting clinically significant prostate cancer, family 
history was a significant predictor (OR, 6.32; 95% CI; 2.790–14.298; p<0.001).
Conclusions: A family history of prostate cancer in Korean men was a significant factor for predicting prostate cancer. Moreover, 
significant differences in the aggressive features of the disease were identified between patients with and without a family history.
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INTRODUCTION
Family history and family or personal history of high-
risk germline mutations are included in the National 
Comprehensive Cancer Network (NCCN) guidelines for the 
early detection of prostate cancer [1]; however, it was not 
considered as a stronger factor than the serum prostate-
specific antigen (PSA) level for the diagnosis of prostate 
cancer. Furthermore, prostate cancer in men with a family 
history is not more likely to be aggressive. However, these 
findings have been based on studies that were conducted 
in Western countries, and the conclusions drawn from the 
results may not apply to Asians.
Prostate cancer in Asian countries is more advanced 
and aggressive than that in Western countries [2-4], and 
this might result from differences in races. Family history 
and genes such as BRCA1, BRCA2, and ATM may help 
explain the differences of prostate cancer according to the 
races; however, studies about clinical features of hereditary 
or familial prostate cancer in Asian men are scarce. 
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Furthermore, the impact of family history on the diagnosis 
of prostate cancer among Asian men remains controversial 
[5,6]. In this study, we evaluated whether a positive family 
history of prostate cancer is associated with the diagnosis 
and aggressiveness of the prostate cancer among Korean 
men.
MATERIALS AND METHODS
1. Study population and data collection
This retrospective study was approved by the Gangnam 
Severance Hospital Insti tutional Review Board (approval 
number: 3-2016-0151), and informed consent was obtained 
from all individual participants included in the study. All 
procedures involving human participants were performed 
in accordance with the ethical standards of the institutional 
research committee and with the 1964 Declaration of 
Helsinki and subsequent amendments or comparable ethical 
standards. Six hundred and two patients who underwent a 
transrectal ultrasound-guided prostate biopsy from March 
2015 to September 2017 were initially selected. The indication 
for prostate biopsy was persistent clinically suggestive 
findings of prostate cancer, such as an elevated PSA level 
≥3.0 ng/mL, steadily increasing PSA level, and abnormal 
results of a digital rectal examination. Patients (n=10) who 
underwent confirmative prostate biopsy after treatment for 
previously diagnosed prostate cancer were excluded.
Patient demographics, including age, body mass index, 
the use of 5α-reductase inhibitors, PSA level, prostate volume, 
presence of previous prostate biopsy history, biopsy Gleason 
score, and clinical staging according to the 7th edition of 
the American Joint Committee on Cancer, were obtained 
[7]. Magnetic resonance imaging and whole-body bone scans 
were routinely assessed in patients diagnosed with prostate 
cancer. The images were interpreted by radiology specialists 
in the urology department of our hospital, and the tumour 
pathology was determined by pathology specialists. Clinically 
significant prostate cancer was defined as a Gleason score 
≥7.
All patients who underwent prostate biopsy were asked 
whether they had a family history of  prostate cancer. 
Information on family history was obtained via a self-
administered questionnaire at baseline. A positive family 
history was defined as having a father and/or one or more 
brothers with a diagnosis of prostate cancer. Men whose 
family history could not be determined, such as those with 
no brothers or whose father died early, were considered to 
have a negative family history.
2. Statistical analysis
Continuous variables are expressed as a median (inter-
quartile range). Categorical variables are reported as the 
number of occurrences and frequency. The Mann–Whitney 
U test and the Pearson chi-square test were used to perform 
statistical comparisons of  continuous and categorical 
variables, respectively. In the analysis for predicting the 
diagnosis of  prostate cancer and clinically significant 
prostate cancer, multiple logistic regressions were used. All 
statistical comparisons were conducted with IBM SPSS 
Statistics version 23.0 (IBM Corp., Armonk, NY, USA). A 
p-value <0.05 was considered statistically significant.
Table 1. Baseline characteristics of the patients
Characteristic Total Family history(-) Family history(+) p-value
No. of patients 602 (100.0) 561 (93.2) 41 (6.8)
Age (y) 68.3 (62.1–74.0) 68.4 (62.2–74.2) 64.0 (60.8–70.4) 0.032
PSA level (ng/mL) 6.28 (4.53–11.13) 6.27 (4.61–11.16) 6.88 (4.28–11.10) 0.915
Prostate volume (cm3) 39.5 (29.4–51.8) 39.6 (29.5–52.3) 36.3 (28.8–49.1) 0.339
PSA density (ng/mL/cm3) 0.17 (0.11–0.31) 0.17 (0.11–0.31) 0.18 (0.12–0.41) 0.587
History of prostate biopsy (yes) 118 (19.6) 107 (19.1) 11 (26.8) 0.228
Diagnosis of prostate cancer 299 (49.7) 271 (48.3) 28 (68.3) 0.014
Gleason score (n=299) 0.009
   ≤6 98 (32.8) 95 (35.1) 3 (10.7)
   ≥7 201 (67.2) 176 (64.9) 25 (89.3)
Clinical stage (n=267) 0.812
   ≤cT2 170 (56.9) 154 (56.8) 16 (57.1)
   ≥cT3 97 (32.4) 87 (32.1) 10 (35.7)
Data are presented as number (%) or median (interquartile range).
PSA, prostate-specific antigen.
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RESULTS
1. Patient characteristics
The baseline characteristics of the study patients are 
summarised in Table 1. Of 602 patients (median age, 68.3 
years; median PSA level, 6.28 ng/mL) included in this study, 
299 (49.7%) patients were diagnosed with prostate cancer. Of 
41 (6.8%) patients identified with a positive family history, 
28 patients were diagnosed with prostate cancer. The median 
patient age, number of  patients diagnosed with prostate 
cancer, and number of patients diagnosed with clinically 
significant prostate cancer were significantly higher in 
patients with family history of  prostate cancer (p=0.032, 
p=0.014, and p=0.009, respectively). 
2. Association of a family history with the diagno-
sis of prostate cancer
Multivariate analysis was performed to investigate the 
predictors of patients diagnosed with prostate cancer (Table 
2). Age (odds ratio [OR], 1.07; 95% confidence interval [CI], 
1.043–1.098; p<0.001), PSA level (OR, 1.16; 95% CI, 1.105–1.210; 
p<0.001), prostate volume (OR, 0.95; 95% CI, 0.934–0.960; 
p<0.001), and presence of a family history (OR, 2.99; 95% CI, 
1.330–6.704; p=0.008) were identified as significant predictors 
of prostate cancer diagnosis.
3. Association of a family history with the diagno-
sis of clinically significant prostate cancer
Of the patients diagnosed with prostate cancer, 201 
(67.2%) patients were identif ied as having clinically 
significant prostate cancer. Multivariate analysis was 
performed to investigate the predictors of  diagnosis of 
clinically significant prostate cancer (Table 3). Age (OR, 1.04; 
95% CI, 1.013–1.069; p=0.004), the PSA level (OR, 1.12; 95% CI, 
1.068–1.164; p<0.001), prostate volume (OR, 0.95; 95% CI, 0.935–
0.968; p<0.001), PSA density (≥0.15 ng/mL/cm3) (OR, 2.01; 95% 
CI, 1.098–3.685; p=0.024), and presence of a family history 
(OR, 6.32; 95% CI, 2.790–14.298; p<0.001) were identified as 
significant predictors of clinically significant prostate cancer.
DISCUSSION
The impact of a family history of prostate cancer on the 
diagnosis and clinicopathologic outcomes of prostate cancer 
has been investigated in several studies [8-15]. Previous 
studies revealed that the heritability of  prostate cancer 
carries a 2.1 to 2.5-fold increased risk of developing prostate 
cancer [13-15]. Moreover, the presence of a family history 
is associated with a higher potential risk of  a diagnosis 
of prostate cancer at a younger age (≤65 years) (OR, 4.3) 
[14]. Our study also showed that patients with familial 
history had significantly younger age. From this result and 
findings from other studies, we may infer that familial 
history of prostate cancer is related to age at diagnosis. The 
Table 2. Results of univariate and multivariate analyses of the factors for predicting the diagnosis of prostate cancer
Univariate analysis Multivariate analysis
OR (95% CI) p-value OR (95% CI) p-value
Age 1.07 (1.046–1.091) <0.001 1.07 (1.043–1.098) <0.001
PSA level 1.11 (1.073–1.150) <0.001 1.16 (1.105–1.210) <0.001
Prostate volume 0.97 (0.960–0.981) <0.001 0.95 (0.934–0.960) <0.001
PSA density ≥0.15 ng/mL/cm3 4.60 (3.210–6.593) <0.001 1.10 (0.642–1.900) 0.721
History of prostate biopsy 0.61 (0.405–0.918) 0.018 0.65 (0.396–1.050) 0.078
Family history 2.31 (1.170–4.542) 0.016 2.99 (1.330–6.704) 0.008
OR, odds ratio; CI, confidence interval; PSA, prostate-specific antigen. 
Table 3. Results of univariate and multivariate analyses of the factors for predicting the diagnosis of clinically significant prostate cancer
Univariate analysis Multivariate analysis
OR (95% CI) p-value OR (95% CI) p-value
Age 1.05 (1.030–1.077) <0.001 1.04 (1.013–1.069) 0.004
PSA level 1.12 (1.082–1.152) <0.001 1.12 (1.068–1.164) <0.001
Prostate volume 0.97 (0.961–0.984) <0.001 0.95 (0.935–0.968) <0.001
PSA density ≥0.15 ng/mL/cm3 7.91 (4.987–12.544) <0.001 2.01 (1.098–3.685) 0.024
History of prostate biopsy 0.56 (0.352–0.889) 0.014 0.68 (0.387–1.189) 0.175
Family history 3.42 (1.780–6.563) <0.001 6.32 (2.790–14.298) <0.001
OR, odds ratio; CI, confidence interval; PSA, prostate-specific antigen.
445Investig Clin Urol 2019;60:442-446. www.icurology.org
Association of family history with prostate cancer
one possible reason would be that patients with a family 
history might have undergone PSA testing earlier than the 
general population due to the consciousness of their health 
of the prostate. However, there could be hereditary factors 
of prostate cancer and those with familial prostate cancer 
history would be susceptible to prostate cancer at younger 
age. We do not know the clear reason why those with family 
history of prostate cancer were younger, but it is certain 
that we should perform PSA screening for those with 
familial history of prostate cancer at younger age. Future 
studies would be needed to confirm the exact age for the 
initiation of PSA screening with familial prostate cancer 
history.
Several studies reported that men with a first-degree 
family history have a higher possibility of tumour detection 
with a low-grade Gleason score (≤6). Azzouzi et al. [16] 
reported that cases of familial prostate cancer do not show 
any progression, as compared with sporadic cases. Raheem 
et al. [17] reported that patients with first-degree relatives 
who died of  prostate cancer do not have an increased 
likelihood of  high-risk or aggressive prostate cancer or 
shorter-term risk of  biochemical recurrence compared to 
those who did not die of  prostate cancer. No difference 
in prostate cancer mortality was observed in terms of 
family history [18]. Contrary to previous studies, our study 
demonstrated that family history of prostate cancer was a 
novel predictor for the diagnosis of the both prostate cancer 
and clinically significant prostate cancer (Gleason score ≥7). 
Therefore, a positive family history was associated with 
aggressive features of  the disease at diagnosis. However, 
our group previously reported that the presence of a family 
history was not identified as a prognostic factor of overall 
survival for prostate cancer among Korean population [19]. 
Additionally, no statistically significant differences were 
found in several parameters, including the Gleason score 
and pathologic stage, tumour volume, and positive surgical 
margin, between patients with and without a family history. 
Furthermore, family history had no prognostic effect on 
biochemical failure. However, our previous study confined 
the study population to those who have undergone radical 
prostatectomy [19]. Therefore, the prostate cancer was more 
aggressive in those group compared to the study population 
in this study and this might be the reason why the family 
history was reported as significant predictor of clinically 
significant prostate cancer with higher Gleason scores only 
in this study. Since previous study only confined to the 
patients who have undergone radical prostatectomy, we 
provided more clinically practical group of  patients who 
have underwent transrectal ultrasound-guided prostate 
biopsy according to the indication. Therefore, we believe 
that patients with a family history of  prostate cancer 
are diagnosed with high-grade prostate cancer, but worse 
survival cannot be presumed.
The impact of family history on the diagnosis of prostate 
cancer was mainly conducted in Western countries. To 
the best of our knowledge, published reports in Asians are 
scarce and remain controversial. Nagata et al. [5] reported 
no association between family history and prostate cancer 
risk. However, a recent study reported that family history 
is strongly associated with an increased risk for prostate 
cancer [6]. This study, which analysed more patients than 
previous studies, showed that the presence of  a family 
history of prostate cancer was a significant risk factor of 
prostate cancer diagnosis in Korean populations. Prostate 
cancer is more advanced and aggressive in Asian countries 
than in Western countries [2-4]. No data about the epide-
miology or ethnicity, particularly the clinical features 
of  hereditary or familial prostate cancer in Asian men, 
are available. We found that the proportion of clinically 
significant prostate cancer (Gleason score ≥7) was higher 
in men with a family history of prostate cancer than in 
men without a family history. The NCCN guidelines state 
that BRACA1/2 pathogenic mutation carriers are associated 
with an increased risk of  prostate cancer before age 65 
years, and prostate cancer in men with germline BRCA2 
mutations occurs earlier and is more likely to be associated 
with prostate cancer mortality [1]. In order to clarify the 
epidemiology of prostate cancer in Korean men and explain 
our findings, we plan to investigate the genetic factors, such 
as gene mutations and chromosomal, and gene or single 
nucleotide polymorphisms.
This is the largest study to determine that family history 
is a predicting factor for prostate cancer diagnosis in Korean 
population. Moreover, this study is the first one in that men 
with a family history of prostate cancer were younger and 
had a higher Gleason score than those without a family 
history at the time of diagnosis. Despite these strengths, 
this study has several limitations. First, the sample size of 
our enrolled patients was small, which imposed limitations 
on the statistical power of  the results. However, it was 
sufficient to evaluate the effect of family history on the 
diagnosis of  prostate cancer among Korean men. This 
finding can be verified in future large-scale studies. Second, 
the stratification according to the definition of clinically 
significant prostate cancer lacked standardisation; thus, a 
different data collection method could yield different results. 
Despite these limitations, further large, population-based 
studies are warranted to elucidate the epidemiology of a 
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family history of prostate cancer. We are designing future 
studies to identify the predictive value of a family history of 
prostate cancer by investigating genetic characteristics.
CONCLUSIONS
This study demonstrated the importance of  family 
history of  prostate cancer among Korean populations 
in predicting prostate cancer. There were statistically 
significant differences not only in detection of  prostate 
cancer but also in the aggressiveness of the disease between 
patients with and without a family history of  prostate 
cancer.
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